18.03.2025 21:47:53
|
Why Novo Nordisk Stock Outpaced the Market on Tuesday
Novo Nordisk (NYSE: NVO), the Danish company best known as the maker of weight loss drug Wegovy, expanded a little on the stock exchange Tuesday. The company was one of the rare enterprises seeing an increase in price on what was generally a down day for the market; it closed 1% higher, against the 1.1% decline of the bellwether S&P 500 (SNPINDEX: ^GSPC).That gravity-defying boost was due in no small part to an analyst's note distributed before market open. UBS's Jo Walton reiterated the Swiss bank's buy recommendation on Novo Nordisk stock at a price target of 750 Danish kroner ($110) per share. It wasn't immediately apparent why the analyst published the update. Although it's been something of an up-and-down stock so far this year, Novo Nordisk remains the pacesetter in the market for GLP-1 drugs, of which Wegovy -- indicated specifically for weight loss -- is the product most identified with the category.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Novo Nordisk (spons. ADRs)mehr Nachrichten
Analysen zu Novo Nordisk (spons. ADRs)mehr Analysen
Aktien in diesem Artikel
Novo Nordisk (spons. ADRs) | 74,20 | 1,64% |
|